We would like to provide you with an update on current projects, look back to a very successful year 2024 and give you an outlook on 2025. After the assembly, we look forward to a get-together for mutual exchange. The get-together is kindly supported by AbbVie and ULLRICH&NAUMANN.
Registration for bioRN members only.
Please contact: Sibylle Geilenberg, email:sg@biorn.org
register now
Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]
EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions. Scientists from EMBL Heidelberg were part of a […]
Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]
You are currently viewing a placeholder content from Mailchimp. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
